Human herpesvirus six: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 12: Line 12:
{{SI}}
{{SI}}


__NOTOC__
{{CMG}}




Line 32: Line 34:


--> but no definitive link has been established.
--> but no definitive link has been established.
==Treatment==
===Antimicrobial Regimen===


:* '''Human herpesvirus 6 treatment'''<ref name="pmid25582535">{{cite journal| author=Tong LX, Worswick SD| title=Viral infections in acute graft-versus-host disease: a review of diagnostic and therapeutic approaches. | journal=J Am Acad Dermatol | year= 2015 | volume= 72 | issue= 4 | pages= 696-702 | pmid=25582535 | doi=10.1016/j.jaad.2014.12.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25582535  }} </ref><ref name="pmid15653828">{{cite journal| author=De Bolle L, Naesens L, De Clercq E| title=Update on human herpesvirus 6 biology, clinical features, and therapy. | journal=Clin Microbiol Rev | year= 2005 | volume= 18 | issue= 1 | pages= 217-45 | pmid=15653828 | doi=10.1128/CMR.18.1.217-245.2005 | pmc=PMC544175 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15653828  }} </ref>
::* Preferred regimen: supportive therapy
::* Note: If patient is immunocompromised, there are no antiviral regimens stablished as there are no clinical trials to validate their use on these cases. Consider administering [[Ganciclovir]], [[Acyclovir]], [[Foscarnet]] {{or}} [[Cidofovir]].<ref name="pmid22819486">{{cite journal| author=Wolz MM, Sciallis GF, Pittelkow MR| title=Human herpesviruses 6, 7, and 8 from a dermatologic perspective. | journal=Mayo Clin Proc | year= 2012 | volume= 87 | issue= 10 | pages= 1004-14 | pmid=22819486 | doi=10.1016/j.mayocp.2012.04.010 | pmc=PMC3538396 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22819486  }} </ref><ref name="pmid15653828">{{cite journal| author=De Bolle L, Naesens L, De Clercq E| title=Update on human herpesvirus 6 biology, clinical features, and therapy. | journal=Clin Microbiol Rev | year= 2005 | volume= 18 | issue= 1 | pages= 217-45 | pmid=15653828 | doi=10.1128/CMR.18.1.217-245.2005 | pmc=PMC544175 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15653828  }} </ref>
==References==
==References==
{{reflist|2}}
{{reflist|2}}
Line 42: Line 50:
[[de:Humanes Herpesvirus 6]]
[[de:Humanes Herpesvirus 6]]
[[fr:Herpèsvirus humain type 6]]
[[fr:Herpèsvirus humain type 6]]
 
[[Category:Infectious Disease Project]]
{{WH}}
{{WH}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 19:27, 7 August 2015

Human herpesvirus 6
Electron micrograph of HHV-6
Electron micrograph of HHV-6
Virus classification
Group: Group I (dsDNA)
Family: Herpesviridae
Genus: Roseolovirus
species

Human herpesvirus 6 (HHV-6)

WikiDoc Resources for Human herpesvirus six

Articles

Most recent articles on Human herpesvirus six

Most cited articles on Human herpesvirus six

Review articles on Human herpesvirus six

Articles on Human herpesvirus six in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Human herpesvirus six

Images of Human herpesvirus six

Photos of Human herpesvirus six

Podcasts & MP3s on Human herpesvirus six

Videos on Human herpesvirus six

Evidence Based Medicine

Cochrane Collaboration on Human herpesvirus six

Bandolier on Human herpesvirus six

TRIP on Human herpesvirus six

Clinical Trials

Ongoing Trials on Human herpesvirus six at Clinical Trials.gov

Trial results on Human herpesvirus six

Clinical Trials on Human herpesvirus six at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Human herpesvirus six

NICE Guidance on Human herpesvirus six

NHS PRODIGY Guidance

FDA on Human herpesvirus six

CDC on Human herpesvirus six

Books

Books on Human herpesvirus six

News

Human herpesvirus six in the news

Be alerted to news on Human herpesvirus six

News trends on Human herpesvirus six

Commentary

Blogs on Human herpesvirus six

Definitions

Definitions of Human herpesvirus six

Patient Resources / Community

Patient resources on Human herpesvirus six

Discussion groups on Human herpesvirus six

Patient Handouts on Human herpesvirus six

Directions to Hospitals Treating Human herpesvirus six

Risk calculators and risk factors for Human herpesvirus six

Healthcare Provider Resources

Symptoms of Human herpesvirus six

Causes & Risk Factors for Human herpesvirus six

Diagnostic studies for Human herpesvirus six

Treatment of Human herpesvirus six

Continuing Medical Education (CME)

CME Programs on Human herpesvirus six

International

Human herpesvirus six en Espanol

Human herpesvirus six en Francais

Business

Human herpesvirus six in the Marketplace

Patents on Human herpesvirus six

Experimental / Informatics

List of terms related to Human herpesvirus six


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Human Herpesvirus Six (HHV-6) is one of the eight known viruses that are members of the human herpesvirus family.

Groupings

HHV-6 is a member of the betaherpesviridae (subfamily of the herpesvirinae) which also includes HHV-7 and Cytomegalovirus (HHV-5 or HCMV). There are two subtypes of HHV-6 termed HHV-6A and HHV-6B.

Occurrence

HHV-6B is responsible for up to 93% of primary infections in Europe and North America. Such infections usually cause fever, with exanthem subitum (Roseola/rash)[1] only being observed in 10% of cases. HHV-6 primary infections account for up to 20% of infant hospitalizations in the United States and are associated with several more severe complications, such as encephalitis, lymphadenopathy, myocarditis and myelosuppression.

After primary infection, latency is established in myeloid and bone marrow progenitors and exists for the life time of the host. The virus periodically re-activates from this latent state, with HHV-6 DNA being detectable in 20-25% of healthy adults in the United States. In the immunocompetent setting, these re-activations are often asymptomatic, but in immunosuppressed, individuals there can be serious complications.

HHV-6 re-activation causes severe disease in transplant recipients and can lead to graft rejection, often in consort with other betaherpesviridae. Likewise in HIV/AIDS, HHV-6 re-activations cause disseminated infections leading to end organ disease and death. Although up to 100% of the population are exposed (seropositive) to HHV-6, most by 3 years of age, there are rare cases of primary infections in adults. In the United States, these have been linked more with HHV-6A, which is thought to be more pathogenic and more neurotropic and has been linked to several central nervous system-related disorders.

HHV-6 has also been found in multiple sclerosis patients[2] and has been implicated as a co-factor in several other diseases, including chronic fatigue syndrome[3], fibromyalgia, AIDS[4], and temporal lobe epilepsy[5] but no definitive link has been established.

Treatment

Antimicrobial Regimen

  • Human herpesvirus 6 treatment[6][7]
  • Preferred regimen: supportive therapy
  • Note: If patient is immunocompromised, there are no antiviral regimens stablished as there are no clinical trials to validate their use on these cases. Consider administering Ganciclovir, Acyclovir, Foscarnet OR Cidofovir.[8][7]

References

  1. Newly Found Herpes Virus Is Called Major Cause of Illness in Young, New York Times
  2. Prevalence of herpesvirus DNA in MS patients, Acta Neurol Scand
  3. CFS: Evaluation and Treatment, Amer Academy of Family Physicians
  4. HHV-6 and AIDS, Wisconsin Viral Research Group
  5. Fotheringham J, Donati D, Akhyani N, Fogdell-Hahn A, Vortmeyer A, Heiss JD, Williams E, Weinstein S, Bruce DA, Gaillard WD, Sato S, Theodore WH, Jacobson S (2007). "Association of human herpesvirus-6B with mesial temporal lobe epilepsy". PLoS Med. 4 (5): e180. doi:10.1371/journal.pmed.0040180. PMID 17535102.
  6. Tong LX, Worswick SD (2015). "Viral infections in acute graft-versus-host disease: a review of diagnostic and therapeutic approaches". J Am Acad Dermatol. 72 (4): 696–702. doi:10.1016/j.jaad.2014.12.002. PMID 25582535.
  7. 7.0 7.1 De Bolle L, Naesens L, De Clercq E (2005). "Update on human herpesvirus 6 biology, clinical features, and therapy". Clin Microbiol Rev. 18 (1): 217–45. doi:10.1128/CMR.18.1.217-245.2005. PMC 544175. PMID 15653828.
  8. Wolz MM, Sciallis GF, Pittelkow MR (2012). "Human herpesviruses 6, 7, and 8 from a dermatologic perspective". Mayo Clin Proc. 87 (10): 1004–14. doi:10.1016/j.mayocp.2012.04.010. PMC 3538396. PMID 22819486.

de:Humanes Herpesvirus 6 Template:WH Template:WikiDoc Sources